Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 4
2019 9
2020 5
2021 5
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. Mittica G, et al. Among authors: giannone g. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512470 Free article. Review.
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana IG, Reinius MAV, Giannone G, Lewsley LA, Stobo J, McQueen J, Bryson G, Eldridge M; BriTROC Investigators; Macintyre G, Markowetz F, Brenton JD, McNeish IA. Smith P, et al. Among authors: giannone g. Nat Commun. 2023 Jul 20;14(1):4387. doi: 10.1038/s41467-023-39867-7. Nat Commun. 2023. PMID: 37474499 Free PMC article.
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA. Banerjee S, et al. Among authors: giannone g. JAMA Oncol. 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. JAMA Oncol. 2023. PMID: 36928279 Free PMC article. Clinical Trial.
Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G. Ghisoni E, et al. Among authors: giannone g. Future Oncol. 2019 Jun;15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. Future Oncol. 2019. PMID: 31074636 Review.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G, Tuninetti V, Ghisoni E, Genta S, Scotto G, Mittica G, Valabrega G. Giannone G, et al. Int J Mol Sci. 2019 May 12;20(9):2353. doi: 10.3390/ijms20092353. Int J Mol Sci. 2019. PMID: 31083638 Free PMC article. Review.
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G. Genta S, et al. Among authors: giannone g. Expert Opin Biol Ther. 2018 Apr;18(4):359-367. doi: 10.1080/14712598.2018.1425679. Epub 2018 Jan 10. Expert Opin Biol Ther. 2018. PMID: 29307234 Review.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Musacchio L, Valsecchi AA, Salutari V, Valabrega G, Camarda F, Tuninetti V, Giannone G, Bartoletti M, Marchetti C, Pignata S, Fagotti A, Scambia G, Di Maio M, Lorusso D. Musacchio L, et al. Among authors: giannone g. Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24. Cancer Treat Rev. 2022. PMID: 36063572 Review.
Is there a role for immunotherapy in ovarian cancer?
Giannone G, Valabrega G. Giannone G, et al. Ann Transl Med. 2019 Dec;7(Suppl 8):S276. doi: 10.21037/atm.2019.12.13. Ann Transl Med. 2019. PMID: 32015995 Free PMC article. No abstract available.
33 results